INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49501, 18585, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49502, 18687, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49503, 18688, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49504, 18689, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49505, 18690, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49506, 19512, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49507, 19513, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49508, 20412, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49509, 20413, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49510, 20414, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49511, 25472, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49512, 25473, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49513, 25690, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49514, 29143, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49515, 29787, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49516, 30442, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49517, 30456, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49518, 30495, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49519, 33743, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', '"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49520, 1078, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49521, 1773, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49522, 1786, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49523, 2610, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49524, 2617, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49525, 2618, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49526, 2672, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49527, 2674, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49528, 2677, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49529, 4387, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49530, 4388, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49531, 4416, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49532, 6737, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49533, 8940, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49534, 16358, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49535, 16421, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49536, 17021, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49537, 17416, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49538, 18542, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49539, 18544, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49540, 18546, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49541, 18584, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49542, 18585, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49543, 18687, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49544, 18688, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49545, 18689, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49546, 18690, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49547, 19512, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49548, 19513, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49549, 20412, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49550, 20413, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49551, 20414, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49552, 25472, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49553, 25473, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49554, 25690, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49555, 29143, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49556, 29787, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49557, 30442, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49558, 30456, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49559, 30495, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49560, 33743, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49561, 1078, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49562, 1773, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49563, 1786, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49564, 2610, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49565, 2617, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49566, 2618, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49567, 2672, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49568, 2674, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49569, 2677, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49570, 4387, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49571, 4388, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49572, 4416, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49573, 6737, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49574, 8940, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49575, 16358, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49576, 16421, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49577, 17021, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49578, 17416, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49579, 18542, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49580, 18544, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49581, 18546, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49582, 18584, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49583, 18585, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49584, 18687, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49585, 18688, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49586, 18689, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49587, 18690, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49588, 19512, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49589, 19513, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49590, 20412, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49591, 20413, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49592, 20414, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49593, 25472, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49594, 25473, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49595, 25690, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49596, 29143, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49597, 29787, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49598, 30442, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49599, 30456, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49600, 30495, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49601, 33743, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49602, 1078, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49603, 1773, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49604, 1786, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49605, 2610, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49606, 2617, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49607, 2618, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49608, 2672, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49609, 2674, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49610, 2677, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49611, 4387, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49612, 4388, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49613, 4416, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49614, 6737, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49615, 8940, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49616, 16358, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49617, 16421, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49618, 17021, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49619, 17416, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49620, 18542, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49621, 18544, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49622, 18546, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49623, 18584, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49624, 18585, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49625, 18687, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49626, 18688, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49627, 18689, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49628, 18690, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49629, 19512, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49630, 19513, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49631, 20412, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49632, 20413, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49633, 20414, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49634, 25472, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49635, 25473, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49636, 25690, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49637, 29143, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49638, 29787, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49639, 30442, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49640, 30456, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49641, 30495, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49642, 33743, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49643, 1078, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49644, 1773, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49645, 1786, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49646, 2610, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49647, 2617, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49648, 2618, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49649, 2672, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49650, 2674, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49651, 2677, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49652, 4387, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49653, 4388, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49654, 4416, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49655, 6737, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49656, 8940, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49657, 16358, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49658, 16421, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49659, 17021, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49660, 17416, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49661, 18542, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49662, 18544, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49663, 18546, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49664, 18584, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49665, 18585, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49666, 18687, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49667, 18688, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49668, 18689, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49669, 18690, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49670, 19512, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49671, 19513, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49672, 20412, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49673, 20413, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49674, 20414, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49675, 25472, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49676, 25473, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49677, 25690, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49678, 29143, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49679, 29787, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49680, 30442, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49681, 30456, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49682, 30495, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49683, 33743, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49684, 1078, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49685, 1773, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49686, 1786, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49687, 2610, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49688, 2617, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49689, 2618, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49690, 2672, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49691, 2674, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49692, 2677, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49693, 4387, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49694, 4388, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49695, 4416, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49696, 6737, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49697, 8940, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49698, 16358, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49699, 16421, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49700, 17021, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49701, 17416, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49702, 18542, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49703, 18544, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49704, 18546, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49705, 18584, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49706, 18585, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49707, 18687, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49708, 18688, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49709, 18689, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49710, 18690, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49711, 19512, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49712, 19513, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49713, 20412, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49714, 20413, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49715, 20414, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49716, 25472, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49717, 25473, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49718, 25690, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49719, 29143, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49720, 29787, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49721, 30442, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49722, 30456, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49723, 30495, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49724, 33743, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49725, 1078, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49726, 1773, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49727, 1786, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49728, 2610, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49729, 2617, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49730, 2618, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49731, 2672, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49732, 2674, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49733, 2677, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49734, 4387, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49735, 4388, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49736, 4416, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49737, 6737, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49738, 8940, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49739, 16358, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49740, 16421, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49741, 17021, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49742, 17416, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49743, 18542, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49744, 18544, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49745, 18546, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49746, 18584, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49747, 18585, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49748, 18687, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49749, 18688, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49750, 18689, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49751, 18690, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49752, 19512, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49753, 19513, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49754, 20412, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49755, 20413, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49756, 20414, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49757, 25472, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49758, 25473, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49759, 25690, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49760, 29143, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49761, 29787, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49762, 30442, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49763, 30456, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49764, 30495, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49765, 33743, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49766, 1078, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49767, 1773, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49768, 1786, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49769, 2610, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49770, 2617, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49771, 2618, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49772, 2672, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49773, 2674, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49774, 2677, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49775, 4387, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49776, 4388, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49777, 4416, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49778, 6737, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49779, 8940, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49780, 16358, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49781, 16421, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49782, 17021, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49783, 17416, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49784, 18542, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49785, 18544, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49786, 18546, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49787, 18584, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49788, 18585, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49789, 18687, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49790, 18688, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49791, 18689, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49792, 18690, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49793, 19512, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49794, 19513, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49795, 20412, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49796, 20413, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49797, 20414, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49798, 25472, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49799, 25473, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49800, 25690, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49801, 29143, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49802, 29787, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49803, 30442, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49804, 30456, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49805, 30495, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49806, 33743, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49807, 4310, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49808, 4313, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49809, 4322, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49810, 17993, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49811, 17994, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49812, 17995, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49813, 18364, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49814, 18366, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49815, 18479, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49816, 18480, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49817, 18481, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49818, 18483, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49819, 18484, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49820, 18487, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49821, 18488, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49822, 18490, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49823, 18493, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49824, 18494, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49825, 4310, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49826, 4313, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49827, 4322, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49828, 17993, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49829, 17994, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49830, 17995, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49831, 18364, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49832, 18366, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49833, 18479, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49834, 18480, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49835, 18481, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49836, 18483, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49837, 18484, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49838, 18487, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49839, 18488, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49840, 18490, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49841, 18493, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49842, 18494, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49843, 4310, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49844, 4313, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49845, 4322, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49846, 17993, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49847, 17994, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49848, 17995, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49849, 18364, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49850, 18366, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49851, 18479, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49852, 18480, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49853, 18481, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49854, 18483, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49855, 18484, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49856, 18487, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49857, 18488, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49858, 18490, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49859, 18493, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49860, 18494, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49861, 4310, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49862, 4313, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49863, 4322, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49864, 17993, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49865, 17994, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49866, 17995, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49867, 18364, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49868, 18366, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49869, 18479, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49870, 18480, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49871, 18481, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49872, 18483, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49873, 18484, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49874, 18487, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49875, 18488, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49876, 18490, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49877, 18493, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49878, 18494, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49879, 4310, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49880, 4313, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49881, 4322, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49882, 17993, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49883, 17994, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49884, 17995, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49885, 18364, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49886, 18366, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49887, 18479, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49888, 18480, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49889, 18481, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49890, 18483, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49891, 18484, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49892, 18487, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49893, 18488, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49894, 18490, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49895, 18493, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49896, 18494, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', '"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49897, 32029, 'Esketamine', 'Hypertension', 'Esketamine causes an increase in systolic and/or diastolic blood pressure at all recommended doses.  The increase peaks approximately 40 minutes after administration of esketamine, and lasts for about 4 hours.  Blood pressure should be monitored prior and after administration.  If baseline blood pressure is elevated before administering (e.g., >140 mmHg systolic, >90 mmHg diastolic), consider the risks of short term increases in blood pressure and benefit of treatment in patients with treatment- resistant depression (TRD).  Do not administer esketamine if an increase in blood pressure or intracranial pressure poses a serious risk.  Esketamine is contraindicated in patients with aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels), arteriovenous malformations, or a history of intracerebral hemorrhage.', '3', '"Product Information. Spravato (esketamine)." Janssen Pharmaceuticals  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49898, 32029, 'Esketamine', 'Psychotic Disorders', 'Esketamine can cause dissociative or perceptual changes (including distortion of time, space and illusions), derealization and depersonalization.  Patients with psychosis must be carefully assessed before administering esketamine, and treatment should be initiated only if the benefit outweighs the risk.  Patients must be monitored by a healthcare provider for at least 2 hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.', '3', '"Product Information. Spravato (esketamine)." Janssen Pharmaceuticals  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49899, 32029, 'Esketamine', 'Substance-Related Disorders', 'Esketamine, is a Schedule III controlled substance (CIII), and may be subject to abuse and diversion.  Assess each patient''s risk for abuse or misuse prior to prescribing esketamine and monitor all patients receiving treatment for the development of these behaviors or conditions, including drug- seeking behavior, while on therapy.  Individuals with a history of drug abuse or dependence are at greater risk; therefore, use careful consideration prior to treatment of individuals with a history of substance use disorder and monitor for signs of abuse or dependence.', '3', '"Product Information. Spravato (esketamine)." Janssen Pharmaceuticals  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49900, 32029, 'Esketamine', 'Hepatic Insufficiency', 'Esketamine has not been studied in patients with severe hepatic impairment (Child-Pugh class C).  Use in this population is not recommended.  Additionally, the mean esketamine AUC and t1/2 values were higher in patients with moderate hepatic impairment compared to those with normal hepatic function.  Patients with moderate hepatic impairment may need to be monitored for adverse reactions for a longer period of time.', '2', '"Product Information. Spravato (esketamine)." Janssen Pharmaceuticals  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49901, 1561, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49902, 1663, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49903, 3131, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49904, 3455, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49905, 3711, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49906, 4166, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49907, 4395, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49908, 4399, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49909, 4400, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49910, 4403, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49911, 4404, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49912, 4408, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49913, 4527, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49914, 4607, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49915, 4608, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49916, 4675, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49917, 5551, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49918, 5556, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49919, 5719, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49920, 5764, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49921, 6973, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49922, 7315, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49923, 8808, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49924, 8809, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49925, 8810, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49926, 8812, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49927, 9472, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49928, 9557, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49929, 10325, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49930, 11656, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49931, 13590, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49932, 13591, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49933, 14536, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49934, 14537, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49935, 15693, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49936, 18290, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49937, 18552, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49938, 18553, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49939, 18555, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49940, 18556, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49941, 18557, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49942, 18558, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49943, 18560, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49944, 18562, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49945, 18563, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49946, 18564, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49947, 18567, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49948, 18568, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49949, 18569, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49950, 18570, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49951, 18571, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49952, 18572, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49953, 18573, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49954, 18574, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49955, 18763, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49956, 22026, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49957, 22480, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49958, 22481, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49959, 22590, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49960, 22591, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49961, 23540, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49962, 23541, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49963, 23543, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49964, 23544, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49965, 23545, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49966, 23547, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49967, 23549, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49968, 23550, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49969, 23552, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49970, 23644, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49971, 24260, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49972, 24261, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49973, 24329, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49974, 25431, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49975, 25432, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49976, 27531, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49977, 27532, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49978, 28258, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49979, 29282, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49980, 30014, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49981, 30192, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49982, 30193, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49983, 30509, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49984, 30571, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49985, 31061, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49986, 31062, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49987, 32814, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49988, 32893, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49989, 33274, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49990, 1561, 'Esomeprazole', 'Liver Diseases', 'Esomeprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment (Child Pugh Class A and B), little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  In severe hepatic impairment (Child Pugh Class C), however, substantial increases in plasma drug concentrations have been demonstrated.  The manufacturer recommends a maximum dosage of 20 mg once daily in patients with severe liver disease.', '2', '"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49991, 1663, 'Esomeprazole', 'Liver Diseases', 'Esomeprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment (Child Pugh Class A and B), little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  In severe hepatic impairment (Child Pugh Class C), however, substantial increases in plasma drug concentrations have been demonstrated.  The manufacturer recommends a maximum dosage of 20 mg once daily in patients with severe liver disease.', '2', '"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49992, 3131, 'Esomeprazole', 'Liver Diseases', 'Esomeprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment (Child Pugh Class A and B), little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  In severe hepatic impairment (Child Pugh Class C), however, substantial increases in plasma drug concentrations have been demonstrated.  The manufacturer recommends a maximum dosage of 20 mg once daily in patients with severe liver disease.', '2', '"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49993, 3455, 'Esomeprazole', 'Liver Diseases', 'Esomeprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment (Child Pugh Class A and B), little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  In severe hepatic impairment (Child Pugh Class C), however, substantial increases in plasma drug concentrations have been demonstrated.  The manufacturer recommends a maximum dosage of 20 mg once daily in patients with severe liver disease.', '2', '"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49994, 3711, 'Esomeprazole', 'Liver Diseases', 'Esomeprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment (Child Pugh Class A and B), little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  In severe hepatic impairment (Child Pugh Class C), however, substantial increases in plasma drug concentrations have been demonstrated.  The manufacturer recommends a maximum dosage of 20 mg once daily in patients with severe liver disease.', '2', '"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49995, 4166, 'Esomeprazole', 'Liver Diseases', 'Esomeprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment (Child Pugh Class A and B), little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  In severe hepatic impairment (Child Pugh Class C), however, substantial increases in plasma drug concentrations have been demonstrated.  The manufacturer recommends a maximum dosage of 20 mg once daily in patients with severe liver disease.', '2', '"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49996, 4395, 'Esomeprazole', 'Liver Diseases', 'Esomeprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment (Child Pugh Class A and B), little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  In severe hepatic impairment (Child Pugh Class C), however, substantial increases in plasma drug concentrations have been demonstrated.  The manufacturer recommends a maximum dosage of 20 mg once daily in patients with severe liver disease.', '2', '"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49997, 4399, 'Esomeprazole', 'Liver Diseases', 'Esomeprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment (Child Pugh Class A and B), little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  In severe hepatic impairment (Child Pugh Class C), however, substantial increases in plasma drug concentrations have been demonstrated.  The manufacturer recommends a maximum dosage of 20 mg once daily in patients with severe liver disease.', '2', '"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49998, 4400, 'Esomeprazole', 'Liver Diseases', 'Esomeprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment (Child Pugh Class A and B), little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  In severe hepatic impairment (Child Pugh Class C), however, substantial increases in plasma drug concentrations have been demonstrated.  The manufacturer recommends a maximum dosage of 20 mg once daily in patients with severe liver disease.', '2', '"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49999, 4403, 'Esomeprazole', 'Liver Diseases', 'Esomeprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment (Child Pugh Class A and B), little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  In severe hepatic impairment (Child Pugh Class C), however, substantial increases in plasma drug concentrations have been demonstrated.  The manufacturer recommends a maximum dosage of 20 mg once daily in patients with severe liver disease.', '2', '"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50000, 4404, 'Esomeprazole', 'Liver Diseases', 'Esomeprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment (Child Pugh Class A and B), little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  In severe hepatic impairment (Child Pugh Class C), however, substantial increases in plasma drug concentrations have been demonstrated.  The manufacturer recommends a maximum dosage of 20 mg once daily in patients with severe liver disease.', '2', '"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
